Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020

Rhea-AI Summary

Cara Therapeutics, a biopharmaceutical company focused on alleviating pruritus by targeting kappa opioid receptors, will hold a conference call on August 10, 2020, at 4:30 p.m. ET to discuss its second quarter 2020 financial results and provide a corporate update. The company is developing KORSUVA™, a KOR agonist, which has shown promising results in reducing itch intensity in clinical trials for chronic kidney disease-associated pruritus. The FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection.

Positive

• KORSUVA has demonstrated statistically significant reductions in itch intensity in Phase 3 trials.
• Successful completion of Phase 2 trial of Oral KORSUVA for CKD pruritus.
• Currently conducting Phase 2 trials for atopic dermatitis and primary biliary cholangitis.

Negative

• None.

STAMFORD, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a conference call and live audio webcast on Monday, August 10, 2020, at 4:30 p.m. ET to report second quarter 2020 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 7669087. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
Janhavi.Mohite@sternir.com

FAQ

What is Cara Therapeutics' upcoming conference call about?

Cara Therapeutics will discuss its second quarter 2020 financial results and provide a corporate update on August 10, 2020.

When is Cara Therapeutics' conference call scheduled?

The conference call is scheduled for August 10, 2020, at 4:30 p.m. ET.

What is the latest development regarding KORSUVA?

KORSUVA has shown significant effectiveness in reducing itch intensity in clinical trials and has been conditionally accepted as the trade name for difelikefalin injection by the FDA.

How is Cara Therapeutics performing in its clinical trials?

Cara successfully completed Phase 2 trials of Oral KORSUVA and is conducting Phase 2 trials in additional pruritus indications.